Item 6. SELECTED FINANCIAL DATA

(dollars in thousands, except per share data)


Income and Share Data:	2014 (1)		2013		2012		2011 (2)		2010
Net sales	$	357,763	$	310,575	$	314,560	$	289,962	$	269,047
Operating income		159,750		158,469		166,209		163,055		156,328
Earnings before income taxes (3)		161,392		160,662		162,195		164,981		156,446
Net earnings		110,948		112,561		112,331		112,302		109,776
Diluted earnings per share		3.00		3.05		3.04		3.02		2.94
Average common and common equivalent shares – diluted (in thousands)		37,005		36,900		37,006		37,172		37,347

Balance Sheet Data as of June 30:	2014		2013		2012		2011		2010
Cash, cash equivalents and short-term available-for-sale investments	$	363,354	$	332,937	$	268,986	$	140,813	$	138,811
Working capital		443,022		377,432		310,757		212,229		184,016
Total assets		862,491		778,098		719,324		617,670		518,816
Total shareholders’ equity		795,265		737,541		674,442		586,122		501,792

Cash Flow Data:	2014		2013		2012		2011		2010
Net cash provided by operating activities	$	136,762	$	123,562	$	126,746	$	127,194	$	111,260
Capital expenditures		13,821		22,454		6,017		3,630		4,644
Cash dividends declared per share		1.23		1.18		1.11		1.07		1.03

Employee Data as of June 30:	2014		2013		2012		2011		2010
Full-time employees		967		789		783		763		684

(1)	The Company acquired Bionostics Holdings, Ltd on July 22, 2013 and Shanghai PrimeGene Bio-Tech Co. on April 30, 2014.

(2)	The Company acquired Boston Biochem, Inc. on April 1, 2011 and Tocris Holdings Limited and subsidiaries on April 28, 2011.

(3)	Earnings before income taxes included acquisition related expenses related to amortization of intangibles, costs recognized on sale of acquired inventories and professional fees associated with acquisition activity, as follows: 2014 – $20.0 million; 2013 – $10.2 million; 2012 – $12.7 million; 2011 – $5.0 million; 2010 – $1.0 million.